A First In-Human Study of Novel PI3K Inhibitor IPI-549 in Patients With Advanced Solid Tumors

May 24, 2017
Jedd D. Wolchok, MD, PhD

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.